The content on this page is designed for Australia. Check courses designed for Canada (EN)

This course has expired. View available courses.

Cardiovascular

What is the role of NT-proBNP in primary care?

Heart failure (HF) is common, associated with significant morbidity and mortality and frequent hospitalisations. Due to population growth, ageing and increased prevalence of related conditions, prevalence of HF and related hospital admissions is expected to rise significantly in the future.

HF symptoms are common, insidious and non-specific which presents a diagnostic challenge in the community, often leading to delay in diagnosis and appropriate management. Clinical guidelines recommend testing plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration early in the evaluation of patients with symptoms suggestive of acute or chronic heart failure (HF). Concentration below the well validated cut-off values allow HF to be confidently ruled out while high concentrations are useful in guiding further investigation, allowing GPs to determine which patients require expedited echocardiography referral.

NT-proBNP testing can thus empower the GP and provide important guidance for collaboration with secondary care. There is also good evidence that NT-proBNP has prognostic value, leading to an evolving role in guiding individualised HF management decisions. Elevated NT-proBNP in patients with type 2 diabetes has been associated with increased risk of developing cardiac disease. At present reimbursement for testing presents a barrier in some circumstances, but in future, NT-proBNP measurement in high risk populations may allow early targeted initiation of preventive measures.


This educational activity was developed by MdBriefCase, with funding from Roche Diagnostics.

DURATION

25 min

PROFESSION

Physician, Specialist

# OF CREDITS

0

ACCREDITATION

Unaccredited

EXPIRY DATE

2023-01-25

Heart failure (HF) is common, associated with significant morbidity and mortality and frequent hospitalisations. Due to population growth, ageing and increased prevalence of related conditions, prevalence of HF and related hospital admissions is expected to rise significantly in the future.

HF symptoms are common, insidious and non-specific which presents a diagnostic challenge in the community, often leading to delay in diagnosis and appropriate management. Clinical guidelines recommend testing plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration early in the evaluation of patients with symptoms suggestive of acute or chronic heart failure (HF). Concentration below the well validated cut-off values allow HF to be confidently ruled out while high concentrations are useful in guiding further investigation, allowing GPs to determine which patients require expedited echocardiography referral.

NT-proBNP testing can thus empower the GP and provide important guidance for collaboration with secondary care. There is also good evidence that NT-proBNP has prognostic value, leading to an evolving role in guiding individualised HF management decisions. Elevated NT-proBNP in patients with type 2 diabetes has been associated with increased risk of developing cardiac disease. At present reimbursement for testing presents a barrier in some circumstances, but in future, NT-proBNP measurement in high risk populations may allow early targeted initiation of preventive measures.


This educational activity was developed by MdBriefCase, with funding from Roche Diagnostics.

Faculty

Dr Anita Sharma (GP), MBBS, FRACGP
Queensland

Professor Andrew Sindone, B. Med (Hons), MD, FRACP, FCSANZ, FNHFA
New South Wales

Learning objectives

Understand how NT-proBNP can be used in primary care to

  1. Diagnose and monitor heart failure
  2. Identify those type 2 diabetes patients at higher risk of developing CVD in the next 12 months, who can then receive cardioprotective treatment and/or referral to a Cardiologist
Cost of course:  
Free
# of credits: 0
Duration: 25 min

FAQs & HELP

MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.

All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.

The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.

Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.

No, registration with MDBriefCase is free!

To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.

If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.

Please note: if you submitted multiple password resets, only the link on the most recent email is valid.

You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.

What is the role of NT-proBNP in primary care?

25 min

Duration

Physician, Specialist

Profession

0

# of credits

Learning Objectives

Understand how NT-proBNP can be used in primary care to

  1. Diagnose and monitor heart failure
  2. Identify those type 2 diabetes patients at higher risk of developing CVD in the next 12 months, who can then receive cardioprotective treatment and/or referral to a Cardiologist

Unaccredited

ACCREDITATION

Cardiovascular

Learning Category

Medication

Topic

0

Price

2023-01-25

Expiry Date

AUS

Region/Language

Course Description

Heart failure (HF) is common, associated with significant morbidity and mortality and frequent hospitalisations. Due to population growth, ageing and increased prevalence of related conditions, prevalence of HF and related hospital admissions is expected to rise significantly in the future.

HF symptoms are common, insidious and non-specific which presents a diagnostic challenge in the community, often leading to delay in diagnosis and appropriate management. Clinical guidelines recommend testing plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration early in the evaluation of patients with symptoms suggestive of acute or chronic heart failure (HF). Concentration below the well validated cut-off values allow HF to be confidently ruled out while high concentrations are useful in guiding further investigation, allowing GPs to determine which patients require expedited echocardiography referral.

NT-proBNP testing can thus empower the GP and provide important guidance for collaboration with secondary care. There is also good evidence that NT-proBNP has prognostic value, leading to an evolving role in guiding individualised HF management decisions. Elevated NT-proBNP in patients with type 2 diabetes has been associated with increased risk of developing cardiac disease. At present reimbursement for testing presents a barrier in some circumstances, but in future, NT-proBNP measurement in high risk populations may allow early targeted initiation of preventive measures.


This educational activity was developed by MdBriefCase, with funding from Roche Diagnostics.

Faculty

Dr Anita Sharma (GP), MBBS, FRACGP
Queensland

Professor Andrew Sindone, B. Med (Hons), MD, FRACP, FCSANZ, FNHFA
New South Wales

Accreditation

Unaccredited